Asymptomatic, nulliparous, heterozygous carriers of the prothrombin gene mutation are 3.6 times as likely as women who do not carry the mutation to experience severe pregnancy complications.
Asymptomatic, nulliparous, heterozygous carriers of the prothrombin gene mutation are 3.6 times as likely as women who do not carry the mutation to experience severe pregnancy complications, including severe preeclampsia, fetal growth restriction less than the fifth percentile for sex and gestation, stillbirth, and neonatal death, according to a prospective cohort study conducted in Australia.
The authors of the study, which involved 1,707 women, found particularly strong associations between heterozygosity for prothrombin gene mutation and placental abruption (odds ratio [OR], 12.15; 95% confidence interval [CI], 2.45-60.39) and between homozygosity or heterozygosity for factor V Leiden and stillbirth (OR, 8.85; 95% CI, 1.60-48.92), although the latter finding involved a very small number of patients (n=6).
They also found that homozygosity for the methylenetetrahydrofolate reductase enzyme (MTHFR) A1298C polymorphism may actually be protective against such adverse pregnancy outcomes, particularly severe fetal growth restriction.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More